

Review Form 1.6

Journal Name:	Asian Journal of Cardiology Research
Manuscript Number:	Ms_AJCR_82228
Title of the Manuscript:	OPINE-IT: Oral AntiPlatelets Usage Pattern IN Acute Coronary Syndrome: Exploring The Indian Ticagrelor Experience
Type of the Article	

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journalajcr.com/index.php/AJCR/editorial-policy>)

Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<ol style="list-style-type: none"> The year of study should be specified. (Data was collected in which year? 2018, 2019 or 2020?) Reference document No. 1 should be more up-to-date. The sum of the percentages in question 2 is less than 100%. (57.2%+30.1%+8.2% = 95.5%--> the sum should be 100%) The sum of the percentages in question 3 is more than 100%. (42.4%+32.4%+26.4%=101.2% → the sum should be 100%) Figure 1. ; Number in purple pie should be 11% (11.4% should be estimate to 11%; not 12%) Figure 2. ; prasugrel [3 (4.6- 1.8 %)] were the least preferred in the management of ACS compared to ticagrelor. (Fig. 2) The sum of the percentages in table 2 is less than 100%. (54+19.8+2.6+2 = only 78.4%) The reference guideline should be more up-to-date such as ESC 2020 Acute Coronary Syndromes (ACS) in Patients Presenting without Persistent ST-Segment Elevation / 2021 ACC/AHA/SCAI Guideline of Coronary Artery Revascularization, these guidelines have recommendations about the preferable choice of antiplatelets usage in ACS patients. 	
Minor REVISION comments	<ol style="list-style-type: none"> Abstract It should not exceed 300 words in length. 	
Optional/General comments	<ol style="list-style-type: none"> The nature of the question was directed towards ticagrelor, and prasugrel was not mentioned in the article, despite the fact that prasugrel was effective in people receiving coronary stents. 	

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Kitigon Vichairuanthum
Department, University & Country	Kluaynamthai Hospital, Thailand